The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Abstract
Varenicline, a new nicotinic ligand based on the structure of cytisine, has recently been approved by the U.S. Food and Drug Administration for use as a smoking cessation aid. Varenicline has been shown to be a partial agonist of alpha4beta2 receptors, and in equilibrium binding assays, it is highly selective for the alpha4beta2 receptor. In this study, we have examined the functional activity of varenicline at a variety of rat neuronal nicotinic receptors expressed in Xenopus laevis oocytes and assayed under two-electrode voltage clamp. We also find that varenicline is a potent, partial agonist at alpha4beta2 receptors, with an EC50 of 2.3 +/- 0.3 microM and an efficacy (relative to acetylcholine) of 13.4 +/- 0.4%. Varenicline has lower potency and higher efficacy at alpha3beta4 receptors, with an EC50 of 55 +/- 8 microM and an efficacy of 75 +/- 6%. Varenicline also seems to be a weak partial agonist at alpha3beta2 and alpha6-containing receptors, with an efficacy <10%. It is remarkable that varenicline is a potent, full agonist at alpha7 receptors with an EC50 of 18 +/- 6 microM and an efficacy of 93 +/- 7% (relative to acetylcholine). Thus, whereas varenicline is a partial agonist at some heteromeric neuronal nicotinic receptors, it is a full agonist at the homomeric alpha7 receptor. Some combination of these actions may be involved in the mechanism of varenicline as a smoking cessation aid.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline is a partial agonist of α4/β2* nAChRs (Coe et al., 2005), but also activates α7-type nAChRs (Mihalak et al., 2006).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Mihalak et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [6]
In the citing paper
“It acts as a partial agonist at α3β4-, α2-, and α6-containing nAChRs, and a full agonist at α7 nAChRs [238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [238]
In the citing paper
“It is a derivative of cytisine, a plant alkaloid with selective affinity and partial agonism for α4β2 nAChRs [236–238].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [237]
In the citing paper
“subsequent work showed that varenicline had a significant effect at ␣7 nAChRs, ␣34* nAChRs, and 5-hydroxytryptamine type 3 receptors”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Mihalak et al., 2006
In the citing paper
“varenicline, a partial agonist of the α4β2 nAChRs and a full α7 agonist developed to aid smoking cessation in humans (Mihalak, Carroll, & Luetje, 2006), has also been found to have antidepressant effects in the FST (Rollema et al., 2009).”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Mihalak et al., 2006
Citations
Cites
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Nicotinic Receptors at the Amino Acid Level
Corringer, P., Novère, N. G. L., & Changeux, J. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.431 · Cited by 832
Luetje, C., & Patrick, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00837.1991 · Cited by 558
Jensen, A. A., Frølund, B., Liljefors, T., & Krogsgaard‐Larsen, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040219e · Cited by 549
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36376-1 · Cited by 405
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997) · PubMed · Cited by 392
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit
Papke, R. L., & Heinemann, S. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09896-7 · Cited by 259
Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis
Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249
Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses
Kuryatov, A., Olale, F., Cooper, J., Choi, C. H., & Lindstrom, J. M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00144-1 · Cited by 224
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 460
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 460
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Steensland, P., Simms, J. A., Holgate, J. Y., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 368
2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment
Barua, R. S., Rigotti, N. A., Benowitz, N. L., Cummings, K. M., Jazayeri, M., Morris, P. B., Ratchford, E. V., Sarna, L., Stecker, E. C., & Wiggins, B. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.027 · Cited by 391
Shi, Y., Weingarten, T. N., Mantilla, C. B., Hooten, W. M., & Warner, D. O. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ebdaf9 · Cited by 315
Ayers, J. W., Ribisl, K. M., & Brownstein, J. S. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.12.007 · Cited by 298
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 285
The Dynamics of DNA Methylation in Schizophrenia and Related Psychiatric Disorders
Grayson, D. R., & Guidotti, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.125 · Cited by 280
Jones, C. K., Byun, N. E., & Bubser, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.199 · Cited by 241
Varenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222
Neuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 201
Ultrapotent chemogenetics for research and potential clinical applications
Magnus, C. J., Lee, P. H., Bonaventura, J., Zemla, R., Gomez, J. L., Ramirez, M. H., Hu, X., Galván, A., Basu, J., Michaelides, M., et al. (2019) · Science · doi:10.1126/science.aav5282 · Cited by 197
The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function
Sinkus, M. L., Graw, S. L., Freedman, R., Ross, R. G., Lester, H. A., & Leonard, S. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.006 · Cited by 191
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub5 · Cited by 187
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162
Smoking cessation and reduction in people with chronic mental illness
Tidey, J. W., & Miller, M. E. (2015) · BMJ · doi:10.1136/bmj.h4065 · Cited by 174
How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use?
McKee, S. A., & Weinberger, A. H. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185549 · Cited by 164
Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential
Romanelli, M., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., & Gualtieri, F. (2007) · ChemMedChem · doi:10.1002/cmdc.200600207 · Cited by 171
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers
Benowitz, N. L., Pipe, A., West, R., Hays, J. T., Tonstad, S., McRae, T. D., Lawrence, D., Aubin, L. S., & Anthenelli, R. M. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0397 · Cited by 167
The role of the habenula in drug addiction
Velasquez, K. M., Molfese, D. L., & Salas, R. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00174 · Cited by 155
(-)-Cytisine and derivatives: synthesis, reactivity, and applications.
Rouden, J., Lasne, M., Blanchet, J., & Baudoux, J. (2014) · Chemical Reviews · doi:10.1021/cr400307e · Cited by 113
Hong, L. E. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.83 · Cited by 150
Plebani, J. G., Lynch, K. G., Yu, Q. P., Pettinati, H. M., O’Brien, C. P., & Kampman, K. M. (2012) · Cited by 142
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143
Nicotinic acetylcholine receptors in neuropathic and inflammatory pain
Hone, A. J., & McIntosh, J. M. (2017) · FEBS Letters · doi:10.1002/1873-3468.12884 · Cited by 135
Fowler, C. D., Arends, M. A., & Kenny, P. J. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830c360e · Cited by 131
Hendrickson, L. M., Guildford, M. J., & Tapper, A. R. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00029 · Cited by 140
Tuesta, L. M., Fowler, C. D., & Kenny, P. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.026 · Cited by 135
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Loughead, J., Ray, R., Wileyto, E. P., Ruparel, K., Sanborn, P. M., Siegel, S. J., Gur, R. C., & Lerman, C. E. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.016 · Cited by 123
Pharmacotherapy of amphetamine‐type stimulant dependence: An update
Brensilver, M., Heinzerling, K. G., & SHOPTAW, S. J. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 125
Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease
Quik, M., Zhang, D., McGregor, M., & Bordia, T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.014 · Cited by 113
Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy.
Tutka, P., & Zatoński, W. A. (2006) · PubMed · Cited by 125
Neurobiological Mechanisms of Nicotine Reward and Aversion
Wills, L. P., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000299 · Cited by 134
Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine
Navarrete, F., Rodríguez‐Arias, M., Martín‐García, E., Navarro, D., García‐Gutiérrez, M. S., Aguilar, M. A., Aracil-Fernández, A., Berbel, P. J., Miñarro, J., Maldonado, R. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.157 · Cited by 122
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3
Zesiewicz, T. A., Greenstein, P. E., Sullivan, K. L., Wecker, L., Miller, A., Jahan, I., Chen, R., & Perlman, S. (2012) · Neurology · doi:10.1212/wnl.0b013e318247cc7a · Cited by 119
Salim, A. A., Chin, Y., & Kinghorn, A. D. (2008) · Springer eBooks · doi:10.1007/978-3-540-74603-4_1 · Cited by 115
Brunzell, D. H., & McIntosh, J. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.299 · Cited by 114
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub3 · Cited by 116
Shim, J.-C., Jung, D.-U., Jung, S. S., Seo, Y.-S., Cho, D.-M., Lee, J.-H., Lee, S.-W., Kong, B.-G., Kang, J.-W., Oh, M., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.238 · Cited by 112
Smith, R. C., Lindenmayer, J., Davis, J. M., Cornwell, J. A., Noth, K., Gupta, S., Sershen, H. W., & Lajtha, Á. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.001 · Cited by 107
Ericson, M., Löf, E., Stomberg, R., & Söderpalm, B. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147058 · Cited by 109
Graef, S., Schönknecht, P., Sabri, O., & Hegerl, U. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2153-8 · Cited by 107
Smoking Behaviour and Mental Health Disorders—Mutual Influences and Implications for Therapy
Minichino, A., Bersani, F. S., Calò, W. K., Spagnoli, F., Francesconi, M., Vicinanza, R., Chiaie, R. D., & Biondi, M. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10104790 · Cited by 110
Wirta, D., Vollmer, P. M., Paauw, J. D., Chiu, K.-H., Henry, E., Striffler, K., Nau, J. A., Wirta, D., Rubin, J. M., Reilly, C. D., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.11.004 · Cited by 105
Mechanisms and genetic factors underlying co-use of nicotine and alcohol or other drugs of abuse
Cross, S. J., Lotfipour, S., & Leslie, F. M. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1209512 · Cited by 101
Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.013 · Cited by 98
Wouda, J. A., Riga, D., de Vries, W., Stegeman, M., van Mourik, Y., Schetters, D., Schoffelmeer, A. N. M., Pattij, T., & Vries, T. J. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2213-8 · Cited by 99
Kamens, H. M., Andersen, J., & Picciotto, M. R. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1759-1 · Cited by 101
Hendrickson, L. M., Zhao-Shea, R., Pang, X.-Y., Gardner, P. D., & Tapper, A. R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2601-10.2010 · Cited by 101
Wing, V. C., Wass, C., Soh, D. W., & George, T. P. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06261.x · Cited by 99
Medications for alcohol use disorders: An overview
Akbar, M. D., Egli, M., Cho, Y., Song, B., & Noronha, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 101
Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
De Biasi, M., & Salas, R. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-mr-355 · Cited by 95
Litten, R. Z., Wilford, B. B., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Substance Abuse · doi:10.1080/08897077.2015.1133472 · Cited by 94
Quik, M., Perez, X. A., & Grady, S. R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.001 · Cited by 97
Melis, M., Scheggi, S., Carta, G., Madeddu, C., Lecca, S., Luchicchi, A., Cadeddu, F., Frau, R., Fattore, L., Fadda, P., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4647-12.2013 · Cited by 97
Schmaal, L., Berk, L., Hulstijn, K. P., Cousijn, J., Wiers, R. W., & van den Brink, W. (2011) · European Addiction Research · doi:10.1159/000327682 · Cited by 93
Parikh, V., Kutlu, M. G., & Gould, T. J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.020 · Cited by 97
Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 94
Trends in Cell-Based Electrochemical Biosensors
Ding, L., Du, D., Zhang, X., & Ju, H. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786848514 · Cited by 90
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88
Varenicline Augmentation in Depressed Smokers: An 8-Week, Open-Label Study
Philip, N. S., Carpenter, L. L., Tyrka, A. R., Whiteley, L. B., & Price, L. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04441 · Cited by 86
The Duplicated α7 Subunits Assemble and Form Functional Nicotinic Receptors with the Full-length α7
Wang, Y., Xiao, C., Indersmitten, T., Freedman, R., Leonard, S. S., & Lester, H. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.582858 · Cited by 86
Keever, K. R., Yakubenko, V. P., & Hoover, D. B. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106758 · Cited by 82
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
Namba, M. D., Leyrer-Jackson, J. M., Nagy, E. K., Olive, M. F., & Neisewander, J. L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.650785 · Cited by 76
LeSage, M. G., Shelley, D., Ross, J. T., Carroll, F. I., & Corrigall, W. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.024 · Cited by 79
Nicotinic mechanisms influencing synaptic plasticity in the hippocampus
Placzek, A. N., Zhang, T. A., & Dani, J. A. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.39 · Cited by 77
Salas, R., Main, A., Gangitano, D., & De Biasi, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.017 · Cited by 76
Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy☆
Henningfield, J. E., Shiffman, S. S., Ferguson, S. G., & Gritz, E. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.011 · Cited by 77
Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease
McDaid, J., Mustaly-Kalimi, S., & Stutzmann, G. E. (2020) · Cells · doi:10.3390/cells9122655 · Cited by 73
Huang, L. Z., Campos, C., Ly, J., Carroll, F. I., & Quik, M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.032 · Cited by 76
Functional alterations by a subgroup of neonicotinoid pesticides in human dopaminergic neurons
Loser, D., Hinojosa, M. G., Blum, J. H., Schaefer, J., Brüll, M., Johansson, Y., Suciu, I., Grillberger, K., Danker, T., Möller, C., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03031-1 · Cited by 77
Jimenez-Ruiz, C. A., Berlin, I., & Hering, T. (2009) · Drugs · doi:10.2165/00003495-200969100-00003 · Cited by 76
Igari, M., Alexander, J. C., Ji, Y. R., Qi, X., Papke, R. L., & Bruijnzeel, A. W. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.216 · Cited by 75
Structure–odour relationships reviewed in the postgenomic era
de March, C. A., Ryu, S., Sicard, G., Moon, C., & Golebiowski, J. (2015) · Flavour and Fragrance Journal · doi:10.1002/ffj.3249 · Cited by 71
Portugal, G. S., & Gould, T. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.006 · Cited by 73
Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70
Causal Factors of Increased Smoking in ADHD: A Systematic Review
van Amsterdam, J., van der Velde, B., Schulte, M. H. J., & van den Brink, W. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1334066 · Cited by 70
Billen, B., Spurný, R., Brams, M., van Elk, R., Valera-Kummer, S., Yakel, J. L., Voets, T., Bertrand, D., Smit, A. B., & Ulens, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116397109 · Cited by 71
Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor
Lummis, S. C. R., Thompson, A. J., Bencherif, M., & Lester, H. A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185306 · Cited by 71
Smith, R. C., Amiaz, R., Si, T., Maayan, L. A., Jin, H., Boules, S., Sershen, H. W., Li, C., Ren, J., Liu, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0143490 · Cited by 83
Feduccia, A. A., Simms, J. A., Mill, D., Yi, H. Y., & Bartlett, S. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12690 · Cited by 70
Results of an initial clinical trial of varenicline for the treatment of cocaine dependence
Plebani, J. G., Lynch, K. G., Yu, Q. P., Pettinati, H. M., O’Brien, C. P., & Kampman, K. M. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.08.025 · Cited by 68
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Ebbert, J. O. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s10620 · Cited by 67
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 72
The Role of the Habenula in Nicotine Addiction
Baldwin, P. R., Alanis, R., & Salas, R. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s1-002 · Cited by 67
Gao, B.-X., Hierl, M., Clarkin, K., Juan, T., Nguyen, H. Q., van der Valk, M., Deng, H. X., Guo, W., Lehto, S. G., Matson, D. J., et al. (2010) · Pain · doi:10.1016/j.pain.2010.01.007 · Cited by 67
The Glycine Receptor—A Functionally Important Primary Brain Target of Ethanol
Söderpalm, B., Lidö, H. H., & Ericson, M. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13483 · Cited by 68
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66
Nicotine and Nicotinic Receptor Drugs
Quik, M., Bordia, T., Zhang, D., & Perez, X. A. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.07.005 · Cited by 69
Metadata
- Authors
- Mihalak, K. B., Carroll, F. I., & Luetje, C. W.
- Affiliations
- University of Miami (US)
- RTI International (US)
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 70
- Issue
- 3
- Pages
- 801-805
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2141246891
- Cited by
- 558
- References
- 26
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 7 · 2023: 23 · 2022: 14 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 22 · 2017: 32 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 48 · 2012: 36
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Miami
- U.S. Food and Drug Administration
- National Heart, Lung, and Blood Institute (T32HL007188)
- National Institute of Mental Health (MH-66038, R01MH066038)
- National Institute on Drug Abuse (R01DA012001, DA12001, DA08102, R01DA008102)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- varenicline, neuronal nicotinic acetylcholine receptors, alpha4beta2 receptor, partial agonists, full agonists, receptor selectivity, smoking cessation, cytisine derivatives
- MeSH terms
- Varenicline, Animals, Benzazepines, Neurons, Oocytes, Quinoxalines, Receptors, Nicotinic, Xenopus laevis, Nicotinic Agonists, Rats, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
